Cutaneous amyloid is a biomarker in early ATTRv neuropathy and progresses across disease stages

Abstract excerpt

OBJECTIVE: To determine the sensitivity and specificity of cutaneous amyloid deposition in relation to patient-reported measures in the earliest disease stage of hereditary ATTR amyloidosis (ATTRv). METHODS: In a cross-sectional study, we analyzed 88 individuals with TTR mutations, 47 of whom were in the earliest disease stage and without clinically evident neuropathy, 12 healthy controls, and 13 disease controls...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Alzheimer's disease research and treatments
• Share to Amyloidosis: Diagnosis, Treatment, Outcomes
• Share to Skin and Cellular Biology Research